|
Gene: TLE1 |
Gene summary for TLE1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TLE1 | Gene ID | 7088 |
Gene name | TLE family member 1, transcriptional corepressor | |
Gene Alias | ESG | |
Cytomap | 9q21.32 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q04724 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7088 | TLE1 | Pt13.b | Human | Liver | HCC | 2.84e-18 | 4.93e-02 | 0.0251 |
7088 | TLE1 | Pt13.c | Human | Liver | HCC | 5.10e-05 | -3.44e-01 | 0.0076 |
7088 | TLE1 | Pt14.b | Human | Liver | HCC | 9.50e-05 | 1.34e-01 | 0.018 |
7088 | TLE1 | S027 | Human | Liver | HCC | 3.95e-04 | 7.98e-01 | 0.2446 |
7088 | TLE1 | S028 | Human | Liver | HCC | 1.28e-04 | 5.88e-01 | 0.2503 |
7088 | TLE1 | S029 | Human | Liver | HCC | 1.56e-06 | 7.53e-01 | 0.2581 |
7088 | TLE1 | C04 | Human | Oral cavity | OSCC | 8.70e-05 | 5.86e-01 | 0.2633 |
7088 | TLE1 | C21 | Human | Oral cavity | OSCC | 5.74e-16 | 6.81e-01 | 0.2678 |
7088 | TLE1 | C30 | Human | Oral cavity | OSCC | 5.54e-14 | 8.75e-01 | 0.3055 |
7088 | TLE1 | C38 | Human | Oral cavity | OSCC | 2.77e-05 | 6.47e-01 | 0.172 |
7088 | TLE1 | C43 | Human | Oral cavity | OSCC | 4.32e-07 | 2.16e-01 | 0.1704 |
7088 | TLE1 | C46 | Human | Oral cavity | OSCC | 1.57e-05 | 1.62e-01 | 0.1673 |
7088 | TLE1 | C51 | Human | Oral cavity | OSCC | 1.41e-02 | 2.67e-01 | 0.2674 |
7088 | TLE1 | C06 | Human | Oral cavity | OSCC | 5.45e-06 | 1.17e+00 | 0.2699 |
7088 | TLE1 | NEOLP-2 | Human | Oral cavity | NEOLP | 1.57e-03 | 1.07e-01 | -0.0196 |
7088 | TLE1 | NEOLP-3 | Human | Oral cavity | NEOLP | 2.46e-02 | 1.69e-01 | -0.0191 |
7088 | TLE1 | SYSMH1 | Human | Oral cavity | OSCC | 1.49e-05 | -3.95e-02 | 0.1127 |
7088 | TLE1 | SYSMH2 | Human | Oral cavity | OSCC | 1.05e-06 | -9.02e-02 | 0.2326 |
7088 | TLE1 | SYSMH3 | Human | Oral cavity | OSCC | 1.16e-05 | 1.98e-01 | 0.2442 |
7088 | TLE1 | SYSMH4 | Human | Oral cavity | OSCC | 3.12e-03 | -1.96e-01 | 0.1226 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0030111 | Colorectum | AD | regulation of Wnt signaling pathway | 102/3918 | 328/18723 | 8.51e-06 | 2.03e-04 | 102 |
GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
GO:0060070 | Colorectum | AD | canonical Wnt signaling pathway | 90/3918 | 303/18723 | 1.76e-04 | 2.38e-03 | 90 |
GO:0043122 | Colorectum | AD | regulation of I-kappaB kinase/NF-kappaB signaling | 76/3918 | 249/18723 | 2.17e-04 | 2.85e-03 | 76 |
GO:0060828 | Colorectum | AD | regulation of canonical Wnt signaling pathway | 77/3918 | 253/18723 | 2.19e-04 | 2.87e-03 | 77 |
GO:0007249 | Colorectum | AD | I-kappaB kinase/NF-kappaB signaling | 82/3918 | 281/18723 | 6.09e-04 | 6.40e-03 | 82 |
GO:00301112 | Colorectum | MSS | regulation of Wnt signaling pathway | 98/3467 | 328/18723 | 3.37e-07 | 1.36e-05 | 98 |
GO:00160552 | Colorectum | MSS | Wnt signaling pathway | 124/3467 | 444/18723 | 6.06e-07 | 2.26e-05 | 124 |
GO:01987382 | Colorectum | MSS | cell-cell signaling by wnt | 124/3467 | 446/18723 | 7.83e-07 | 2.77e-05 | 124 |
GO:00600702 | Colorectum | MSS | canonical Wnt signaling pathway | 86/3467 | 303/18723 | 1.58e-05 | 3.56e-04 | 86 |
GO:00608282 | Colorectum | MSS | regulation of canonical Wnt signaling pathway | 74/3467 | 253/18723 | 1.99e-05 | 4.26e-04 | 74 |
GO:00431221 | Colorectum | MSS | regulation of I-kappaB kinase/NF-kappaB signaling | 71/3467 | 249/18723 | 7.12e-05 | 1.21e-03 | 71 |
GO:00072491 | Colorectum | MSS | I-kappaB kinase/NF-kappaB signaling | 77/3467 | 281/18723 | 1.51e-04 | 2.19e-03 | 77 |
GO:0030178 | Colorectum | MSS | negative regulation of Wnt signaling pathway | 48/3467 | 170/18723 | 1.23e-03 | 1.18e-02 | 48 |
GO:00160553 | Colorectum | FAP | Wnt signaling pathway | 104/2622 | 444/18723 | 4.92e-08 | 3.92e-06 | 104 |
GO:01987383 | Colorectum | FAP | cell-cell signaling by wnt | 104/2622 | 446/18723 | 6.26e-08 | 4.54e-06 | 104 |
GO:00301113 | Colorectum | FAP | regulation of Wnt signaling pathway | 81/2622 | 328/18723 | 1.44e-07 | 9.03e-06 | 81 |
GO:00608283 | Colorectum | FAP | regulation of canonical Wnt signaling pathway | 62/2622 | 253/18723 | 5.26e-06 | 1.69e-04 | 62 |
GO:00600703 | Colorectum | FAP | canonical Wnt signaling pathway | 71/2622 | 303/18723 | 6.23e-06 | 1.96e-04 | 71 |
Page: 1 2 3 4 5 6 7 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04310 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
hsa043101 | Colorectum | AD | Wnt signaling pathway | 56/2092 | 171/8465 | 1.03e-02 | 3.93e-02 | 2.51e-02 | 56 |
hsa043102 | Colorectum | MSS | Wnt signaling pathway | 53/1875 | 171/8465 | 4.24e-03 | 1.86e-02 | 1.14e-02 | 53 |
hsa043103 | Colorectum | MSS | Wnt signaling pathway | 53/1875 | 171/8465 | 4.24e-03 | 1.86e-02 | 1.14e-02 | 53 |
hsa043104 | Colorectum | FAP | Wnt signaling pathway | 46/1404 | 171/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 46 |
hsa043105 | Colorectum | FAP | Wnt signaling pathway | 46/1404 | 171/8465 | 3.94e-04 | 3.06e-03 | 1.86e-03 | 46 |
hsa043106 | Colorectum | CRC | Wnt signaling pathway | 40/1091 | 171/8465 | 1.01e-04 | 1.57e-03 | 1.07e-03 | 40 |
hsa043107 | Colorectum | CRC | Wnt signaling pathway | 40/1091 | 171/8465 | 1.01e-04 | 1.57e-03 | 1.07e-03 | 40 |
hsa0431010 | Endometrium | AEH | Wnt signaling pathway | 37/1197 | 171/8465 | 4.68e-03 | 2.53e-02 | 1.86e-02 | 37 |
hsa0431013 | Endometrium | AEH | Wnt signaling pathway | 37/1197 | 171/8465 | 4.68e-03 | 2.53e-02 | 1.86e-02 | 37 |
hsa0431022 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa0431032 | Endometrium | EEC | Wnt signaling pathway | 40/1237 | 171/8465 | 1.37e-03 | 8.99e-03 | 6.70e-03 | 40 |
hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa043305 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
hsa0433012 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
hsa0433021 | Oral cavity | NEOLP | Notch signaling pathway | 21/1112 | 62/8465 | 2.23e-05 | 1.87e-04 | 1.18e-04 | 21 |
hsa0431024 | Oral cavity | NEOLP | Wnt signaling pathway | 34/1112 | 171/8465 | 8.05e-03 | 2.88e-02 | 1.81e-02 | 34 |
hsa0433031 | Oral cavity | NEOLP | Notch signaling pathway | 21/1112 | 62/8465 | 2.23e-05 | 1.87e-04 | 1.18e-04 | 21 |
hsa0431034 | Oral cavity | NEOLP | Wnt signaling pathway | 34/1112 | 171/8465 | 8.05e-03 | 2.88e-02 | 1.81e-02 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TLE1 | SNV | Missense_Mutation | c.718N>A | p.Asp240Asn | p.D240N | Q04724 | protein_coding | deleterious(0.03) | probably_damaging(0.91) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
TLE1 | SNV | Missense_Mutation | c.1830N>T | p.Arg610Ser | p.R610S | Q04724 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD | |
TLE1 | SNV | Missense_Mutation | c.1846A>G | p.Thr616Ala | p.T616A | Q04724 | protein_coding | deleterious(0.02) | possibly_damaging(0.557) | TCGA-E9-A1NE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
TLE1 | SNV | Missense_Mutation | c.1852G>C | p.Gly618Arg | p.G618R | Q04724 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
TLE1 | insertion | Frame_Shift_Ins | novel | c.1459_1460insCAGGCTCCGCCTCCGGGGTTTACGCCGTTCTCCTGCCT | p.Val487AlafsTer17 | p.V487Afs*17 | Q04724 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
TLE1 | SNV | Missense_Mutation | c.1465G>A | p.Ala489Thr | p.A489T | Q04724 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-3697-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TLE1 | SNV | Missense_Mutation | c.1679C>T | p.Ala560Val | p.A560V | Q04724 | protein_coding | deleterious(0) | possibly_damaging(0.703) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TLE1 | SNV | Missense_Mutation | c.1748N>A | p.Ser583Asn | p.S583N | Q04724 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TLE1 | SNV | Missense_Mutation | c.1660N>G | p.Leu554Val | p.L554V | Q04724 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TLE1 | SNV | Missense_Mutation | c.1690N>T | p.Pro564Ser | p.P564S | Q04724 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CM-5344-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |